27
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found

      Effects of Neonatal Administration of Octreotide, a Long-Lasting Somatostatin Analogue, on Growth Hormone Regulation in the Adult Rat

      research-article

      Read this article at

      ScienceOpenPublisherPubMed
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The pulsatile pattern of GH secretion slowly develop in the postnatal period concomitantly with the dual network of GHRH and somatostatin (SRIH) hypothalamic neurons. We investigated whether an early postnatal treatment with a long acting SRIH analogue, octreotide, could affect maturation and subsequent operation of those networks in the adult rat. Octreotide administration (5 µg/rat SC) every other day during the first 10 days of life resulted in growth retardation in the adult. In parallel, the amplitude of plasma GH secretory episodes in free moving unanesthetized animals was markedly reduced. The numbers of arcuate GHRH mRNA-containing and periventricular SRIH-mRNA containing neurons were not affected by the treatment. GHRH mRNA levels per neuron however was decreased by 30%, and median eminence GHRH stores by 50%. SRIH expression in the arcuate nucleus was also diminished, as was the number of <sup>125</sup>I-SRIH labeled neurons in that nucleus. The effects of octreotide were compared to the hyposomatotropinemia induced by administration of monosodium glutamate (MSG), every other day during the first 10 days of life. Growth retardation and inhibition of GH secretory episodes in adult rats neonatally treated with MSG were slightly more pronounced than after octreotide. In contrast to octreotide, MSG induced a massive loss of GHRH neurons and a concomitant decrease in <sup>125</sup>I-SRIH binding. Somatostatin did not protect GHRH neurons against the neurotoxic action of MSG since octreotide treatment did not further affect any of the parameters impaired by MSG In conclusion, these experiments demonstrate that neonatally injected octreotide cannot counteract the toxic effect of MSG on arcuate neurons. However, a neonatal treatment with the SRIH agonist affects permanently growth rate and GH pulsatility. This effect is mediated in the hypothalamus by permanently impairing the neural networks that control GH secretion.

          Related collections

          Author and article information

          Journal
          NEN
          Neuroendocrinology
          10.1159/issn.0028-3835
          Neuroendocrinology
          S. Karger AG
          0028-3835
          1423-0194
          1996
          1996
          09 April 2008
          : 63
          : 2
          : 173-180
          Affiliations
          INSERM, Unité 159, Paris, France
          Article
          126954 Neuroendocrinology 1996;63:173–180
          10.1159/000126954
          9053782
          f5686196-bf1d-4750-ab27-75b09bd0ad5d
          © 1996 S. Karger AG, Basel

          Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher. Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug. Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

          History
          : 24 June 1995
          : 13 October 1995
          Page count
          Pages: 8
          Categories
          Somatostatin and Somatoliberin

          Endocrinology & Diabetes,Neurology,Nutrition & Dietetics,Sexual medicine,Internal medicine,Pharmacology & Pharmaceutical medicine
          Growth hormone releasing hormone,Rhythms-ultradian,Growth hormone,Octreotide,Somatostatin,Monosodium glutamate

          Comments

          Comment on this article